ABSTRACT
Johnson and Johnson stock, HIV vaccine patent, human immunodeficiency virus (HIV) acquisition
INFECTIOUS DISEASES, ALLERGY
D.H.B. reports grants from Janssen Vaccines and Prevention outside the submitted work, as well as an HIV vaccine patent licensed to Janssen Vaccines and Prevention. S.C.D. reports grants from the NIH and Gates Foundation during the conduct of the study; and a contract from Janssen Vaccines and Prevention outside the submitted work. M.J.M. reports grants from the National Institute of Allergy and Infectious Diseases (NIAID; funding for Seattle CTU Grant and funding for HVTN Lab) during the study. J.D., D.J.S., J.T., K.C., W.W., and M.P. are employees of Janssen and may hold Johnson and Johnson stock.The ability of vaccine-induced T cells to inhibit viral replication may contribute to protect against human immunodeficiency virus (HIV) acquisition. Here, we tested 